US EditionKamada Expects Third Plasma Collection Site To Support Its Hyper-Immune Plasma Needs And Add Up To $10M In Annual Revenue At Full Capacity
Summary by NewMediaWire
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Kamada Expects Third Plasma Collection Site To Support Its Hyper-Immune Plasma Needs And Add Up To $10M In Annual Revenue At Full Capacity
By Meg Flippin Benzinga DETROIT, MICHIGAN - April 22, 2025 (NEWMEDIAWIRE) - From protecting against infections for people who had a solid organ or bone marrow transplant to treating hepatitis B infection, or preventing deadly Rabies disease in individuals who were exposed to a suspected rabid animal, specialty plasma products are used by healthcare providers around the world to save thousands of lives every day. Kamada Ltd. (NASDAQ: KMDA), a glo…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
